Abstract 5101
Background
Recent reports suggested gaps in knowledge and misperceptions regarding lung cancer (LC) in the general public and physicians respectively. We aimed to further investigate the topic.
Methods
From February 21st to March 22nd, 2019, two online surveys were led in parallel among French people (n = 6001) and physicians (GP, n = 273; pulmonologists, n = 97; oncologists, n = 67). Questions aimed to assess people’s knowledge about LC prevalence, severity, diagnosis, management and treatments, early screening, as well of social stigma, and also understandings from physicians about public perception.
Results
LC was ranked as the 2nd most feared cancer (n = 1980; 33%) and perceived as very or extremely serious by 96% of people (n = 5760). Half of French people (n = 3360) declared knowing at least one other risk factor than tobacco, and except for asbestos (n = 5220; 87%), other potential risk factors were subjects to low to moderate levels of belief. The general population ranked LC as the 3rd easiest cancer to diagnose among French people (n = 2220; 37%) and 57% (n = 3420) believed that diagnosis was made early after symptoms onset. The general population was not aware of the majority of the symptoms beside blood in the sputum and respiratory symptoms. LC was ranked only the 5th cancer (n = 1260; 21%) among those for which medical progress had been the most substantial, whereas physicians ranked it second (n = 201; 46%). Also the public was not aware of therapeutic progress as immunotherapy. Physicians tended to be more optimistic about actual treatment improvement than the public and for 90% of them (n = 393), systematic screening of at-risk population would have a significant impact on mortality data by LC.
Conclusions
Our study confirms the substantial gaps in LC knowledge from the general public and highlights several venues for improvement of communication and public awareness on LC in France.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
J. Cadranel: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Boerhinger Ingelheim; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy: BMS; Advisory / Consultancy: Lilly; Advisory / Consultancy: MSD; Advisory / Consultancy: Roche; Advisory / Consultancy: Takeda. C. Chouaid: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: GSK; Advisory / Consultancy: Roche; Advisory / Consultancy: Sanofi Aventis; Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Advisory / Consultancy: Lilly; Advisory / Consultancy: Novartis; Advisory / Consultancy: Amgen. J.B. Stern: Speaker Bureau / Expert testimony, Fees for presentation in a Medtronic symposium which were donated to our association.: Medtronic. A. Vergnenegre: Advisory / Consultancy, Research grant / Funding (institution): Roche; Research grant / Funding (institution): Chugai; Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Teva; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy: Clovis Oncology. C. Cortot: Full / Part-time employment: AstraZeneca. L. Guery: Full / Part-time employment: AstraZeneca. K. Belkhiria: Full / Part-time employment: AstraZeneca. I. De la Porte: Full / Part-time employment: AstraZeneca. M. Urbieta: Full / Part-time employment: AstraZeneca. M. Perol: Advisory / Consultancy: Novartis; Advisory / Consultancy: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract
4506 - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Presenter: Adel Samson
Session: Poster Display session 3
Resources:
Abstract
1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Presenter: Shinichi Kageyama
Session: Poster Display session 3
Resources:
Abstract
4244 - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
5791 - Ixovex, a novel oncolytic E1B-mutated adenovirus
Presenter: Mohiemen Anwar
Session: Poster Display session 3
Resources:
Abstract
4170 - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial
Presenter: Federica Riccardo
Session: Poster Display session 3
Resources:
Abstract
5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Presenter: Pravin Kaumaya
Session: Poster Display session 3
Resources:
Abstract
5860 - Maternal immunization against ALK as a weapon to fight neuroblastoma
Presenter: Giuseppina Barutello
Session: Poster Display session 3
Resources:
Abstract
4720 - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors
Presenter: Jason Luke
Session: Poster Display session 3
Resources:
Abstract
5717 - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses
Presenter: Stella Martomo
Session: Poster Display session 3
Resources:
Abstract